ARTICLE | Clinical News
Extended-release oxymorphone regulatory update
September 27, 2010 7:00 AM UTC
FDA accepted for filing and granted Priority Review to an NDA from Endo for an extended-release, crush-resistant formulation of oxymorphone to treat moderate to severe pain in patients requiring conti...